British-Swedish biopharmaceutical company AstraZeneca PLC (STO:AZN, LON:AZN, Nasdaq:AZN) on Tuesday announced a USD50bn investment in the United States by 2030 to expand its pharmaceutical manufacturing and research capabilities.

The cornerstone of the investment is a new multi-billion dollar drug substance manufacturing facility in the Commonwealth of Virginia, focused on chronic disease treatments. It is anticipated to be AstraZeneca's largest single facility investment globally, producing drug substances for products such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies.

This advanced site will manufacture small molecules, peptides, and oligonucleotides, leveraging artificial intelligence, automation, and data analytics to optimise production.

Additional US projects include R&D expansion in Gaithersburg, Maryland; a new research hub in Massachusetts; next-generation cell therapy facilities in Maryland and California; and manufacturing expansions in Indiana and Texas.

AstraZeneca expects the US investment to create tens of thousands of skilled jobs and enhance domestic pharmaceutical supply chains.

This initiative supports the company's strategic goal of reaching USD80bn in total revenue by the end of the decade, with half projected to come from the US market.